Downregulation of Electron Transport Chain Genes in Visceral Adipose Tissue in Type 2 Diabetes Independent of Obesity and Possibly Involving Tumor Necrosis Factor-α

  1. Ingrid Dahlman1,
  2. Margaretha Forsgren2,
  3. Annelie Sjögren2,
  4. Elisabet Arvidsson Nordström1,
  5. Maria Kaaman1,
  6. Erik Näslund3,
  7. Anneli Attersand2 and
  8. Peter Arner1
  1. 1Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
  2. 2Biovitrum, Stockholm, Sweden
  3. 3Karolinska Institutet Danderyds Hospital, Stockholm, Sweden
  1. Address correspondence and reprint requests to Prof. Peter Arner, MD, Department of Medicine, Karolinska University Hospital, Huddinge, SE-141 86 Stockholm, Sweden. E-mail: peter.arner{at}ki.se

Abstract

Impaired oxidative phosphorylation is suggested as a factor behind insulin resistance of skeletal muscle in type 2 diabetes. The role of oxidative phosphorylation in adipose tissue was elucidated from results of Affymetrix gene profiling in subcutaneous and visceral adipose tissue of eight nonobese healthy, eight obese healthy, and eight obese type 2 diabetic women. Downregulation of several genes in the electron transport chain was the most prominent finding in visceral fat of type 2 diabetic women independent of obesity, but the gene pattern was distinct from that previously reported in skeletal muscle in type 2 diabetes. A similar but much weaker effect was observed in subcutaneous fat. Tumor necrosis factor-α (TNF-α) is a major factor behind inflammation and insulin resistance in adipose tissue. TNF-α treatment decreased mRNA expression of electron transport chain genes and also inhibited fatty acid oxidation when differentiated human preadipocytes were treated with the cytokine for 48 h. Thus, type 2 diabetes is associated with a tissue- and region-specific downregulation of oxidative phosphorylation genes that is independent of obesity and at least in part mediated by TNF-α, suggesting that impaired oxidative phosphorylation of visceral adipose tissue has pathogenic importance for development of type 2 diabetes.

Footnotes

    • Accepted March 10, 2006.
    • Received November 1, 2005.
« Previous | Next Article »Table of Contents